6978 Stock Overview
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China.
Immunotech Biopharm Ltd Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$4.21|
|52 Week High||HK$17.50|
|52 Week Low||HK$3.21|
|1 Month Change||2.93%|
|3 Month Change||-21.16%|
|1 Year Change||-73.69%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-72.80%|
Recent News & Updates
Will Immunotech Biopharm (HKG:6978) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
|6978||HK Biotechs||HK Market|
Return vs Industry: 6978 underperformed the Hong Kong Biotechs industry which returned -60.5% over the past year.
Return vs Market: 6978 underperformed the Hong Kong Market which returned -25.2% over the past year.
|6978 Average Weekly Movement||14.7%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||6.3%|
|10% most volatile stocks in HK Market||12.6%|
|10% least volatile stocks in HK Market||3.1%|
Stable Share Price: 6978 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: 6978's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer.
Immunotech Biopharm Ltd Fundamentals Summary
|6978 fundamental statistics|
Is 6978 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6978 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.67|
|Net Profit Margin||0.00%|
How did 6978 perform over the long term?See historical performance and comparison